Skip to main content
Premium Trial:

Request an Annual Quote

GATC to Provide Support for MolecularHealth's New Lab

NEW YORK (GenomeWeb News) – MolecularHealth today announced an agreement under which GATC Biotech will provide its laboratory information management system in MolecularHealth's new clinical laboratory.

GATC also will provide protocols, support, and training to MolecularHealth's staff. The deal, MolecularHealth said, will complement its next-generation sequencing offerings and its TreatmentMap oncology treatment decision support platform, which is anticipated to launch in the current quarter.

"GATC Biotech has decades of experience in sequencing technology and services, and a standardized, validated, automated process," MolecularHealth CEO Lloyd Everson said in a statement. "Their proven expertise will be invaluable to our team, as we work to provide personalized, actionable information to cancer patients and their medical teams."

Financial and other terms of the deal were not disclosed.

MolecularHealth separately announced the opening this week of its US headquarters and clinical lab in The Woodlands, Texas. The office and lab occupies about 7,000-square-feet of space, and the company expects to hire approximately 40 people in 2014, it said. The lab will be equipped with Illumina sequencing equipment and offer two tests, a gene panel of more than 500 known cancer genes, and whole exome sequencing of the tumor genome.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more